1.Challenges in coronary heart disease prevention – experiences from a long-term follow-up study in Norway. Sverre E et al., Scandinavian Cardiovascular Journal, Dec 2020

2.Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side-effects: a randomized, double blinded crossover trial. Kristiansen O. et al., European Heart J Cardiovascular Pharmacotherapy, 2020.

3.Is the novel LDL-cholesterol goal <1.4 mmol/L achievable without a PCSK9 inhibitor in a chronic coronary population from clinical practice?Munkhaugen J. et al.,  Eur J Prev Cardiol. May 2020.

4.Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population. Sverre E. et al., BMC Cardiovasc Disord. Feb 2020.

5.Clinical factors, psychological factors and beliefs about statin use in patients with coronary heart disease and self-perceived statin muscle side-effects. Peersen, K. et al., Poster/oral digital presentation, ESC 2020.

6.Drug related metabolites and genetic polymorphisms predict low low-density lipoprotein cholesterol response to atorvastatin treatment in patients with coronary heart disease. Munkhaugen J. et al., Digital poster, ESC 2020.